Overview

PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.

Status:
Active, not recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the effectiveness and safety of LMWH postoperative bridging therapy (standard of care) versus postoperative placebo bridging therapy (experimental arm)for patients with mechanical heart valves or atrial fibrillation or atrial flutter who are at high risk for stroke when warfarin is temporarily interrupted for a procedure.

Phase:

Phase 3

Details

Lead Sponsor:

Lawson Health Research Institute

Collaborators:

Canadian Institutes of Health Research (CIHR)
Pfizer

Treatments:

Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin
Warfarin